Investors warm up to the idea of Pfizer snapping up GSK

Some analysts may be slamming a potential Pfizer ($PFE) buyout of GlaxoSmithKline ($GSK), but some investors are hip to the idea. As Bloomberg reports, options traders are paying record prices for bullish GSK options--and this after the British drugmaker lost $11 billion off its market cap in less than three months. Much of that interest has to do with chatter about a Pfizer takeover, traders told the news service. But it's not the only factor. More from FiercePharma

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.